[Epoch Times, April 16, 2022]A Weibo person with more than 40 million followers publicly questioned Lianhua Qingwen Capsule on the 14th, and said that the regulatory authorities should strictly investigate Yiling Pharmaceutical. The market value of Ling Pharmaceuticals evaporated by nearly 7 billion yuan (RMB, the same below) in one day.
According to the “Securities Times” on April 15, Wang Sicong forwarded a message about Lianhua Qingwen Capsules on Weibo on the 14th, which questioned the efficacy of Lianhua Qingwen Capsules on the virus and said that the regulatory authorities should strictly investigate the Ling Pharmaceutical. This remark quickly fermented on the Internet.
Yiling Pharmaceutical responded that, regarding the news on Weibo, please point out the specific problems and sources, and investors should identify them.
Subsequently, Wang Sicong edited the Weibo, and deleted the words that the regulatory authorities should strictly investigate Yiling Pharmaceutical. On the 16th, the Epoch Times could not see the words that the regulatory authorities should strictly investigate Yiling Pharmaceutical on Wang Sicong’s meager account, but the video he forwarded was still there.
After Wang Sicong posted on Weibo, Yiling Pharmaceutical’s stock price opened lower on the 15th, dropped sharply during the session, and closed down the limit for large orders in the afternoon. As of the close, the stock reported 35.99 yuan per share, with a full-day turnover of 5.44 billion yuan. The latest market value was 60.1 billion yuan, and the market value evaporated nearly 7 billion yuan in one day.
Since the beginning of this year, the stock price of Yiling Pharmaceutical has been trending strongly, hitting a record high of 43.12 yuan in the intraday session on April 12 (after the resumption of rights), and as of the close of trading on April 14, the cumulative increase of the stock has doubled.
The patented traditional Chinese medicine Lianhua Qingwen Capsules produced by Yiling Pharmaceutical Co., Ltd. and the patented traditional Chinese medicine Lianhua Qingwen Granules produced by Beijing Yiling Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, were jointly released by the National Health Commission of the Communist Party of China and the State Administration of Traditional Chinese Medicine. The “New Coronavirus Pneumonia Diagnosis and Treatment Plan (Ninth Trial Version)” is listed as a recommended drug for TCM treatment in the medical observation period and clinical treatment period (confirmed cases) for mild and common types.
Since the outbreak of the epidemic, Lianhua Qingwen Capsules (granules) have been listed as the recommended drugs for the observation period of traditional Chinese medicine treatment in the “New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Version 4/5/6/7/8)”. In the “New Coronary Virus Pneumonia Diagnosis and Treatment Plan (Trial Version 9)” released this time, in addition to continuing to list Lianhua Qingwen Capsules (granules) as a recommended drug during the observation period of traditional Chinese medicine, it also listed it as a clinical treatment period. (Confirmed cases) Recommended medication for mild and common types.
In the first three quarters of 2021, the company’s Lianhua Qingwen products achieved operating income of 3.37 billion yuan, accounting for 41.6% of the company’s total operating income.
A recent research report from Sinolink Securities pointed out that since the outbreak of the epidemic in 2020, Lianhua Qingwen, as one of the “three medicines and three prescriptions”, has been included in the fourth to ninth editions of the new crown diagnosis and treatment plan, and is recommended for observation period, mild disease , Ordinary patients. Lianhua Qingwen will achieve sales of 4.2 billion yuan in 2020, a year-on-year increase of 150%.
Responsible editor: Liu Yi